title: Single-center analysis of the first 304 living-donor liver transplantations in 3 years.
abstract: OBJECTIVE
  Living donor liver transplantations (LDLT) is a definitive treatment for patients with end-stage liver disease (ESLD), especially in the countries with donation problem. Between April 2007 and April 2010, we performed LDLT in 289 patients. Fifteen of the cases required re-transplantations. This study evaluates these 304 consecutive LDLTs donor and recipient outcomes.
  
  
  METHODS
  Complication rates and survival data of the recipients and donors of 304 LDLT cases were analyzed.
  
  
  RESULTS
  All donors are alive and well. Overall complication rate was 27%. Early postoperative recipient complication rate was 51%. Most frequent complication was infection. In the long-term there were 57 biliary stricture and 5 chronic bile fistula cases. Chronic and acute rejection attacks developed in 7 and 103 patients, respectively. Hepatic artery thrombosis rate was 8%. One, two and three year survival rates were 82%, 79% and 75%, respectively. Recipient mortality was 25%, mostly due to vascular complications, septic complications, liver dysfunction and chronic rejection.
  
  
  CONCLUSIONS
  More than 150 liver tranplantations per year in a single center is a challenge in Turkey, where there is a shortage of deceased donor grafts. LDLT is a safe procedure for donors and effective for ESLD. Improvement in surgical technique would provide better outcomes.
authors.forename: Sezai
authors.initials: S
authors.lastname: Yilmaz
authors.forename: Cuneyt
authors.initials: C
authors.lastname: Kayaalp
authors.forename: Cengiz
authors.initials: C
authors.lastname: Ara
authors.forename: Mehmet
authors.initials: M
authors.lastname: Yilmaz
authors.forename: Burak
authors.initials: B
authors.lastname: Isik
authors.forename: Cemalettin
authors.initials: C
authors.lastname: Aydin
authors.forename: Dincer
authors.initials: D
authors.lastname: Ozgor
authors.forename: Abuzer
authors.initials: A
authors.lastname: Dirican
authors.forename: Bora
authors.initials: B
authors.lastname: Barut
authors.forename: Bulent
authors.initials: B
authors.lastname: Unal
authors.forename: Turgut
authors.initials: T
authors.lastname: Piskin
authors.forename: Mustafa
authors.initials: M
authors.lastname: Ates
authors.forename: Ramazan
authors.initials: R
authors.lastname: Kutlu
authors.forename: Huseyin Ilksen
authors.initials: HI
authors.lastname: Toprak
authors.forename: Yasar
authors.initials: Y
authors.lastname: Bayindir
authors.forename: Hale
authors.initials: H
authors.lastname: Kirimlioglu
authors.forename: Murat
authors.initials: M
authors.lastname: Aladag
authors.forename: Murat
authors.initials: M
authors.lastname: Harputluoglu
authors.forename: Ayşe
authors.initials: A
authors.lastname: Selimoglu
authors.forename: Hamza
authors.initials: H
authors.lastname: Karabiber
authors.forename: Kendal
authors.initials: K
authors.lastname: Yalcin
authors.forename: Vedat
authors.initials: V
authors.lastname: Kirimlioglu
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D002648:Child; D002675:Child, Preschool; D006801:Humans; D007223:Infant; D016031:Liver Transplantation / Q000009:adverse effects / Q000401:mortality; D019520:Living Donors; D008875:Middle Aged